All In Biotech

Drug Trial Radar · NCT02105272

Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: Dec 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 237 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

237

Actual

Start

Apr 2014

Primary completion

Mar 2015

Study completion Mar 2015

Sponsor

Sponsor type
Industry
First posted
Apr 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy and safety of OPC-1085EL ophthalmic solution in comparison with latanoprost ophthalmic solution in subjects who are insufficiently responsive to latanoprost ophthalmic solution.

Conditions

  • Glaucoma
  • Ocular Hypertension

Interventions

  • OPC-1085EL ophthalmic solutionDrug

  • Latanoprost ophthalmic solutionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Decrease From Baseline in Intraocular PressureTime frame: Baseline, week 8 predose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Kansai Region, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.